UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
FEBRUARY 5, 2008
------------
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____________________
DIRECTOR/PDMR SHAREHOLDING
TRADING IN NOVO NORDISK SHARES BY BOARD MEMBERS, EXECUTIVES AND ASSOCIATED
PERSONS AS REPORTED TO NOVO NORDISK ON 1 FEBRUARY 2008
In accordance with Section 28a of the Danish Securities Trading Act, Novo
Nordisk is required on a daily basis to publish trading in Novo Nordisk shares
by the company's board members, executives and their associated persons as
reported by those persons to Novo Nordisk.
As from 2004, members of Novo Nordisk's Executive Management and the other
members of the Senior Management Board have participated in a performance-based
incentive programme where a proportion of the calculated shareholder value
creation has been allocated to a joint pool for the participants. For 2004,
252,688 shares were allocated to the joint pool and the market value of the
scheme was expensed in the accounts for 2004. In accordance with the principles
of the incentive programme, the Board of Directors of Novo Nordisk A/S on 30
January 2008 evaluated that the conditions for release of the joint pool of
shares have been fulfilled. Accordingly, the shares in the joint pool were
transferred to 22 current and former members of senior management on 31 January
2008.
Please find below a statement of the transfer of shares to the members of
Executive Management in accordance with the above and the subsequent trading in
these shares by the members of Executive Management.
NAME LARS REBIEN S0RENSEN
REASON FOR REPORTING CHIEF EXECUTIVE OFFICER
FINANCIAL INSTRUMENT AND ID CODE NOVO NORDISK B SHARES DK 006010261
TYPE OF TRANSACTION OTHER TRANSACTION (TRANSFER OF SHARES IN ACCORDANCE WITH
LONG-TERM INCENTIVE PROGRAMME)
DATE OF TRANSACTION 31 JANUARY 2008
PLACE OF TRANSACTION OMX THE NORDIC EXCHANGE COPENHAGEN
VOLUME OF TRANSACTION 26,134 SHARES
TOTAL VALUE OF TRANSACTION DKK 0 (TRANSFERRED IN ACCORDANCE WITH THE LONG-TERM INCENTIVE
PROGRAMME FOR 2004)
NAME LARS REBIEN S0RENSEN
REASON FOR REPORTING CHIEF EXECUTIVE OFFICER
FINANCIAL INSTRUMENT AND ID CODE NOVO NORDISK B SHARES DK 006010261
TYPE OF TRANSACTION SALE OF SHARES
DATE OF TRANSACTION 31 JANUARY 2008
PLACE OF TRANSACTION OMX THE NORDIC EXCHANGE COPENHAGEN
VOLUME OF TRANSACTION 26,134 SHARES
TOTAL VALUE OF TRANSACTION DKK 8,131,855
NAME JESPER BRANDGAARD
REASON FOR REPORTING CHIEF FINANCIAL OFFICER
FINANCIAL INSTRUMENT AND ID CODE NOVO NORDISK B SHARES DK 006010261
TYPE OF TRANSACTION OTHER TRANSACTION (TRANSFER OF SHARES IN ACCORDANCE WITH
LONG-TERM INCENTIVE PROGRAMME)
DATE OF TRANSACTION 31 JANUARY 2008
PLACE OF TRANSACTION OMX THE NORDIC EXCHANGE COPENHAGEN
VOLUME OF TRANSACTION 17,426 SHARES
TOTAL VALUE OF TRANSACTION DKK 0 (TRANSFERRED IN ACCORDANCE WITH THE LONG-TERM INCENTIVE
PROGRAMME FOR 2004)
NAME JESPER BRANDGAARD
REASON FOR REPORTING CHIEF FINANCIAL OFFICER
FINANCIAL INSTRUMENT AND ID CODE NOVO NORDISK B SHARES DK 006010261
TYPE OF TRANSACTION SALE OF SHARES
DATE OF TRANSACTION 31 JANUARY 2008
PLACE OF TRANSACTION OMX THE NORDIC EXCHANGE COPENHAGEN
VOLUME OF TRANSACTION 17,426 SHARES
TOTAL VALUE OF TRANSACTION DKK 5,422,274
NAME LISE KINGO
REASON FOR REPORTING CHIEF OF STAFFS
FINANCIAL INSTRUMENT AND ID CODE NOVO NORDISK B SHARES DK 006010261
TYPE OF TRANSACTION OTHER TRANSACTION (TRANSFER OF SHARES IN ACCORDANCE WITH
LONG-TERM INCENTIVE PROGRAMME)
DATE OF TRANSACTION 31 JANUARY 2008
PLACE OF TRANSACTION OMX THE NORDIC EXCHANGE COPENHAGEN
VOLUME OF TRANSACTION 17,426 SHARES
TOTAL VALUE OF TRANSACTION DKK 0 (TRANSFERRED IN ACCORDANCE WITH THE LONG-TERM INCENTIVE
PROGRAMME FOR 2004)
NAME LISE KINGO
REASON FOR REPORTING CHIEF OF STAFFS
FINANCIAL INSTRUMENT AND ID CODE NOVO NORDISK B SHARES DK 006010261
TYPE OF TRANSACTION SALE OF SHARES
DATE OF TRANSACTION 31 JANUARY 2008
PLACE OF TRANSACTION OMX THE NORDIC EXCHANGE COPENHAGEN
VOLUME OF TRANSACTION 17,426 SHARES
TOTAL VALUE OF TRANSACTION DKK 5,422,274
NAME KARE SCHULTZ
REASON FOR REPORTING CHIEF OPERATING OFFICER
FINANCIAL INSTRUMENT AND ID CODE NOVO NORDISK B SHARES DK 006010261
TYPE OF TRANSACTION OTHER TRANSACTION (TRANSFER OF SHARES IN ACCORDANCE WITH
LONG-TERM INCENTIVE PROGRAMME)
DATE OF TRANSACTION 31 JANUARY 2008
PLACE OF TRANSACTION OMX THE NORDIC EXCHANGE COPENHAGEN
VOLUME OF TRANSACTION 17,426 SHARES
TOTAL VALUE OF TRANSACTION DKK 0 (TRANSFERRED IN ACCORDANCE WITH THE LONG-TERM INCENTIVE
PROGRAMME FOR 2004)
NAME MADS KROGSGAARD THOMSEN
REASON FOR REPORTING CHIEF SCIENCE OFFICER
FINANCIAL INSTRUMENT AND ID CODE NOVO NORDISK B SHARES DK 006010261
TYPE OF TRANSACTION OTHER TRANSACTION (TRANSFER OF SHARES IN ACCORDANCE WITH
LONG-TERM INCENTIVE PROGRAMME)
DATE OF TRANSACTION 31 JANUARY 2008
PLACE OF TRANSACTION OMX THE NORDIC EXCHANGE COPENHAGEN
VOLUME OF TRANSACTION 17,426 SHARES
TOTAL VALUE OF TRANSACTION DKK 0 (TRANSFERRED IN ACCORDANCE WITH THE LONG-TERM INCENTIVE
PROGRAMME FOR 2004)
NAME MADS KROGSGAARD THOMSEN
REASON FOR REPORTING CHIEF SCIENCE OFFICER
FINANCIAL INSTRUMENT AND ID CODE NOVO NORDISK B SHARES DK 006010261
TYPE OF TRANSACTION SALE OF SHARES
DATE OF TRANSACTION 31 JANUARY 2008
PLACE OF TRANSACTION OMX THE NORDIC EXCHANGE COPENHAGEN
VOLUME OF TRANSACTION 17,426 SHARES
TOTAL VALUE OF TRANSACTION DKK 5,422,274
DEFINITIONS AND BACKGROUND INFORMATION:
PUBLICATION
Publication shall take place the day after Novo Nordisk receives sufficient
information on the trading. Publication is only required when the total amount
of transactions of a specific board member/executive and his/her associated
persons in any one calendar year has reached 5,000 euros.
WHO ARE BOARD MEMBERS, EXECUTIVES AND ASSOCIATED PERSONS?
Board members and executives are members of the Board of Directors and Executive
Management, respectively, of Novo Nordisk A/S. Associated persons are defined as
the following persons associated to a board member/executive: 1) spouse or
cohabitant, 2) children under the age of 18 years, 3) relatives defined as
brothers, sisters, parents, grandparents etc, children, grandchildren etc who
have shared the same household with a board member/executive for at least one
year, and 4) any legal person, including a company, a foundation or a
partnership, which is controlled directly or indirectly by a board
member/executive and/or a person mentioned in 1)-3), or to which a board
member/executive and/or a person mentioned in 1)-3) has managerial
responsibilities or economic interests substantially equivalent to the legal
person.
WHAT IS TRADING/TRANSACTION?
Trading is any kind of transaction, including shares purchased or otherwise
acquired, shares sold or otherwise disposed, gifts, mortgages and grants and
exercise of options, but not heritage.
WHAT IS FINANCIAL INSTRUMENT AND ID CODE?
Financial instrument includes shares listed on the OMX The Nordic Exchange
Copenhagen and London Stock Exchange as well as ADRs listed on New York Stock
Exchange, except for ADRs held in 401(k) retirement plan by US-based employees.
The ID code is the code (ISIN DK006010261) of the Novo Nordisk share on OMX The
Nordic Exchange Copenhagen, the code (NVOB) on London Stock Exchange or the code
(NVO) on New York Stock Exchange.
WHAT IS DATE AND PLACE OF TRANSACTION?
Date of transaction is the actual transaction date. The place of transaction is
the actual place of transaction, ie OMX The Nordic Exchange Copenhagen, London
Stock Exchange or New York Stock Exchange.
WHAT IS VOLUME AND VALUE OF TRANSACTION?
The volume of transaction is the number of shares (of DKK 1 nominal value) or
other financial instruments traded. The transaction value is the number of
shares traded multiplied by the transaction price. The exchange rate of the
Danish Central Bank (Nationalbanken) on the date of transaction is used for
calculating the transaction value in DKK in case of shares traded on London
Stock Exchange and ADRs listed on New York Stock Exchange.
For further information please contact:
Novo Nordisk is a healthcare company and a world leader in diabetes care. In
addition, Novo Nordisk has a leading position within areas such as haemostasis
management, growth hormone therapy and hormone replacement therapy. Novo Nordisk
manufactures and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in
80 countries, and markets its products in 179 countries. Novo Nordisk's B shares
are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed
on the New York Stock Exchange under the symbol 'NVO'. For more information,
visit novonordisk.com.
FOR FURTHER INFORMATION PLEASE CONTACT:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
------------------- --------------------
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
-------------------- --------------------
Stock Exchange Announcement no 4 / 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf of the
undersigned, thereunto duly authorized.
Date: FEBRUARY 5, 2008 NOVO NORDISK A/S
---------------------------------------------------
Lars Rebien Sorensen,
President and Chief Executive Officer